ReviewCureus2025
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing burden of type 2 diabetes mellitus (T2D) in India, characterized by rising prevalence, complex treatment regimens, and substantial economic and psychological impact, necessitates a simplified, patient-centered approach to glycemic management. This expert consensus document presents evidence-based recommendations for streamlined glycemic care focused on enhancing treatment adherence, minimizing pill burden, and improving clinical outcomes. An expert panel of endocrinologists and diabetologists convened across eight advisory board meetings to review current evidence and generate practical strategies. Emphasis was placed on the early use of combination therapies, particularly sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, with or without metformin, tailored to individual patient profiles. The consensus underscores the importance of fixed-dose combinations (FDCs) to improve adherence and cost-effectiveness. In addition to pharmacologic strategies, lifestyle interventions, including medical nutrition therapy, physical activity, and sleep hygiene, are advocated. Special considerations are provided for managing T2D with comorbid conditions such as cardiovascular disease, chronic kidney disease, hypertension, obesity, and dyslipidemia, emphasizing the pleiotropic benefits of SGLT-2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The recommendations also address barriers in the Indian healthcare landscape, including limited access to care and treatment inertia. This consensus aims to support clinicians, researchers, and policymakers in implementing an integrative, simplified care model that addresses the multifaceted challenges of T2D management in India. By adopting these recommendations, healthcare providers can enhance patient outcomes, reduce complications, and alleviate the socioeconomic burden of T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.